Log in

NYSE:AVNSAvanos Medical Stock Price, Forecast & News

$28.17
+0.38 (+1.37 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$27.86
Now: $28.17
$29.31
50-Day Range
$23.76
MA: $28.64
$32.11
52-Week Range
$19.46
Now: $28.17
$48.07
Volume338,405 shs
Average Volume410,955 shs
Market Capitalization$1.35 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.22
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes. The company also offers Game Read, a product for pain management and rehabilitation of patients recovering from orthopedic surgery or sports-related injuries; GRPro 2.1, a cold and compression therapy system; Med4Elite, a multi-modality therapy unit; ATX Wraps; and various product accessories. In addition, it sells its products under the ON-Q, COOLIEF, MICROCUFF, MIC-KEY, HOMEPUMP, CORTRAK, and GAME READY brand names. The company markets its products directly to hospitals and other healthcare providers, as well as through third-party distribution channels. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Read More
Avanos Medical logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.41 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone844-428-2667

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$697.60 million
Cash Flow$1.83 per share
Book Value$26.40 per share

Profitability

Net Income$-45,900,000.00

Miscellaneous

Employees4,700
Market Cap$1.35 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive AVNS News and Ratings via Email

Sign-up to receive the latest news and ratings for AVNS and its competitors with MarketBeat's FREE daily newsletter.

Avanos Medical (NYSE:AVNS) Frequently Asked Questions

How has Avanos Medical's stock been impacted by COVID-19 (Coronavirus)?

Avanos Medical's stock was trading at $29.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AVNS stock has decreased by 2.9% and is now trading at $28.17. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Avanos Medical?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Avanos Medical.

When is Avanos Medical's next earnings date?

Avanos Medical is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Avanos Medical.

How were Avanos Medical's earnings last quarter?

Avanos Medical Inc (NYSE:AVNS) released its quarterly earnings data on Wednesday, May, 6th. The company reported $0.16 EPS for the quarter, hitting analysts' consensus estimates of $0.16. The business earned $180.40 million during the quarter, compared to analysts' expectations of $175.15 million. Avanos Medical had a positive return on equity of 4.09% and a negative net margin of 3.07%. The company's quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.15 EPS. View Avanos Medical's earnings history.

What guidance has Avanos Medical issued on next quarter's earnings?

Avanos Medical updated its FY20 earnings guidance on Tuesday, February, 25th. The company provided EPS guidance of $1.00-1.20 for the period, compared to the Thomson Reuters consensus estimate of $1.16. The company issued revenue guidance of +5-7% yr/yr to $732.5-746.4 million, compared to the consensus revenue estimate of $736.83 million.

What price target have analysts set for AVNS?

7 analysts have issued 1-year price targets for Avanos Medical's stock. Their forecasts range from $30.00 to $48.00. On average, they expect Avanos Medical's stock price to reach $36.00 in the next year. This suggests a possible upside of 27.8% from the stock's current price. View analysts' price targets for Avanos Medical.

Has Avanos Medical been receiving favorable news coverage?

News coverage about AVNS stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avanos Medical earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAvanos Medical.

Are investors shorting Avanos Medical?

Avanos Medical saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,810,000 shares, an increase of 12.0% from the March 31st total of 2,510,000 shares. Based on an average daily volume of 421,500 shares, the days-to-cover ratio is currently 6.7 days. Approximately 6.0% of the shares of the stock are short sold. View Avanos Medical's Current Options Chain.

Who are some of Avanos Medical's key competitors?

What other stocks do shareholders of Avanos Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly Clark (KMB), AT&T (T), Alibaba Group (BABA), CVS Health (CVS), Honeywell International (HON), Procter & Gamble (PG), Verizon Communications (VZ), Home Depot (HD), Johnson & Johnson (JNJ) and Altria Group (MO).

Who are Avanos Medical's key executives?

Avanos Medical's management team includes the following people:
  • Mr. Joseph F. Woody, CEO & Director (Age 53)
  • Mr. John W. Wesley, Sr. VP of Legal & Gov. Relations (Age 60)
  • Mr. John R. Tushar, Pres of Global Franchises (Age 57)
  • Mr. Arjun Ranjan Sarker, Sr. VP of International (Age 53)
  • Mr. Warren J. MacHan, Sr. VP of Bus. Strategy & Interim CFO (Age 53)

What is Avanos Medical's stock symbol?

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Who are Avanos Medical's major shareholders?

Avanos Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.35%), Champlain Investment Partners LLC (7.19%), Paradice Investment Management LLC (5.40%), Wellington Management Group LLP (4.71%), State Street Corp (3.73%) and Victory Capital Management Inc. (3.48%). Company insiders that own Avanos Medical stock include Gary Blackford, John W Wesley, Joseph Fralin Woody and Steven E Voskuil. View institutional ownership trends for Avanos Medical.

Which major investors are selling Avanos Medical stock?

AVNS stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Morgan Stanley, Principal Financial Group Inc., Engineers Gate Manager LP, State Street Corp, Arizona State Retirement System, and Palmer Knight Co. View insider buying and selling activity for Avanos Medical.

Which major investors are buying Avanos Medical stock?

AVNS stock was purchased by a variety of institutional investors in the last quarter, including Paradice Investment Management LLC, Confluence Investment Management LLC, Wells Fargo & Company MN, Champlain Investment Partners LLC, Advisor Group Holdings Inc., Wellington Management Group LLP, Deutsche Bank AG, and Geode Capital Management LLC. Company insiders that have bought Avanos Medical stock in the last two years include Gary Blackford, John W Wesley, Joseph Fralin Woody, and Steven E Voskuil. View insider buying and selling activity for Avanos Medical.

How do I buy shares of Avanos Medical?

Shares of AVNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avanos Medical's stock price today?

One share of AVNS stock can currently be purchased for approximately $28.17.

How big of a company is Avanos Medical?

Avanos Medical has a market capitalization of $1.35 billion and generates $697.60 million in revenue each year. The company earns $-45,900,000.00 in net income (profit) each year or $1.07 on an earnings per share basis. Avanos Medical employs 4,700 workers across the globe.

What is Avanos Medical's official website?

The official website for Avanos Medical is avanos.com.

How can I contact Avanos Medical?

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The company can be reached via phone at 844-428-2667 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.